Digest Network Come funziona
Network
/
Società
Ph
Non verificato

Pheast Therapeutics

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

7 comunicati stampa

Guarda tutti i comunicati
03/08/2026
Web e Social Network
Finanza
Industria
Oncologia
Salute
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Pheast Therapeutics to Host Educational KOL Webinar on Emerging Role of Macrophage Checkpoint Biology for the Treatment of Solid Tumors
Fonte
Pheast Therapeutics
Emittente
Business Wire
1.00
0
21/07/2026
Industria
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Igiene alimentare
Medicina - Varie
Pheast Therapeutics Announces Publication in Clinical Cancer Research Demonstrating Robust Anti-Tumor Activity of PHST001
Fonte
Pheast Therapeutics
Emittente
Business Wire
1.00
0
17/03/2026
Biotecnologia
Farmaceutica
Salute
Oncologia
Eventi
Pheast Therapeutics to Present Initial Phase 1a Clinical Data and Two New Preclinical Studies of PHST001, a Novel Anti-CD24 Antibody, at AACR 2026
Fonte
Pheast Therapeutics
Emittente
Business Wire
1.00
0
03/06/2025
Biotecnologia
Igiene alimentare
Salute
Sanità
Farmaceutica
Oncologia
Scienza
Vetrine/Shopping
Medicina - Varie
Industria
Pheast Therapeutics Receives FDA Fast Track Designation for PHST001 for the Treatment of Ovarian Cancer
Fonte
Pheast Therapeutics
Emittente
Business Wire
1.00
0
14/04/2025
Industria
Scienza
Biotecnologia
Medicina - Varie
Salute
Farmaceutica
Sanità
Oncologia
Pheast Therapeutics Announces First Patient Treated in Phase 1 Clinical Trial of PHST001 for Patients with Advanced Solid Tumors
Fonte
Pheast Therapeutics
Emittente
Business Wire
1.00
0
18/02/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Mercato del lavoro
Industria
Pheast Appoints Dr. Raphaël Rousseau as Chief Medical Officer
Fonte
Pheast Therapeutics
Emittente
Business Wire
1.00
0
07/11/2024
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Pheast Presents New Preclinical Data for PHST001, an Anti-CD24 Macrophage Checkpoint Inhibitor, at SITC 2024
Fonte
Pheast Therapeutics
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0